Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
23
02
2023
accepted:
08
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Genome editing by homology directed repair (HDR) is leveraged to precisely modify the genome of therapeutically relevant hematopoietic stem and progenitor cells (HSPCs). Here, we present a new approach to increasing the frequency of HDR in human HSPCs by the delivery of an inhibitor of 53BP1 (named "i53") as a recombinant peptide. We show that the use of i53 peptide effectively increases the frequency of HDR-mediated genome editing at a variety of therapeutically relevant loci in HSPCs as well as other primary human cell types. We show that incorporating the use of i53 recombinant protein allows high frequencies of HDR while lowering the amounts of AAV6 needed by 8-fold. HDR edited HSPCs were capable of long-term and bi-lineage hematopoietic reconstitution in NSG mice, suggesting that i53 recombinant protein might be safely integrated into the standard CRISPR/AAV6-mediated genome editing protocol to gain greater numbers of edited cells for transplantation of clinically meaningful cell populations.
Identifiants
pubmed: 38169468
doi: 10.1038/s41467-023-43413-w
pii: 10.1038/s41467-023-43413-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Informations de copyright
© 2024. The Author(s).
Références
Porteus, M. H. A new class of medicines through DNA editing. N. Engl. J. Med. 380, 947–959 (2019).
pubmed: 30855744
doi: 10.1056/NEJMra1800729
Yeh, C. D., Richardson, C. D. & Corn, J. E. Advances in genome editing through control of DNA repair pathways. Nat. Cell Biol. 21, 1468–1478 (2019).
pubmed: 31792376
doi: 10.1038/s41556-019-0425-z
Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 384, 252–260 (2021).
pubmed: 33283989
doi: 10.1056/NEJMoa2031054
Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216–1224 (2018).
pubmed: 30082871
pmcid: 6107069
doi: 10.1038/s41591-018-0137-0
Dever, D. P. et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539, 384–389 (2016).
pubmed: 27820943
pmcid: 5898607
doi: 10.1038/nature20134
Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358–376 (2018).
pubmed: 29370156
pmcid: 5826598
doi: 10.1038/nprot.2017.143
Bak, R. O. et al. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. Elife 6, e27873 (2017).
Charlesworth, C. T. et al. Priming human repopulating hematopoietic stem and progenitor cells for cas9/sgrna gene targeting. Mol. Ther. Nucleic Acids 12, 89–104 (2018).
pubmed: 30195800
pmcid: 6023838
doi: 10.1016/j.omtn.2018.04.017
Pavel-Dinu, M. et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat. Commun. 10, 1634 (2019).
pubmed: 30967552
pmcid: 6456568
doi: 10.1038/s41467-019-09614-y
Martin, R. M. et al. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat. Commun. 11, 2713 (2020).
pubmed: 32483127
pmcid: 7264334
doi: 10.1038/s41467-020-16455-7
Vaidyanathan, S. et al. High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia. Cell Stem Cell 26, 161–171.e4 (2020).
pubmed: 31839569
doi: 10.1016/j.stem.2019.11.002
DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).
pubmed: 27733558
pmcid: 5500303
doi: 10.1126/scitranslmed.aaf9336
Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235–240 (2014).
pubmed: 24870228
pmcid: 4082311
doi: 10.1038/nature13420
Wang, J. et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263 (2015).
pubmed: 26551060
pmcid: 4842001
doi: 10.1038/nbt.3408
Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551–565.e8 (2019).
pubmed: 30905619
pmcid: 6458988
doi: 10.1016/j.stem.2019.02.019
Hirsch, M. L. et al. Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One 6, e27520 (2011).
pubmed: 22114676
pmcid: 3219675
doi: 10.1371/journal.pone.0027520
Adams, M. M. & Carpenter, P. B. Tying the loose ends together in DNA double strand break repair with 53BP1. Cell Div. 1, 19 (2006).
pubmed: 16945145
pmcid: 1601952
doi: 10.1186/1747-1028-1-19
Yuan, J. & Chen, J. N terminus of CtIP is critical for homologous recombination-mediated double-strand break repair. J. Biol. Chem. 284, 31746–31752 (2009).
pubmed: 19759395
pmcid: 2797245
doi: 10.1074/jbc.M109.023424
Escribano-Díaz, C. et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol. Cell 49, 872–883 (2013).
pubmed: 23333306
doi: 10.1016/j.molcel.2013.01.001
Canny, M. D. et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat. Biotechnol. 36, 95–102 (2018).
pubmed: 29176614
doi: 10.1038/nbt.4021
Nambiar, T. S. et al. Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant. Nat. Commun. 10, 3395 (2019).
pubmed: 31363085
pmcid: 6667477
doi: 10.1038/s41467-019-11105-z
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
pubmed: 23258413
doi: 10.1126/science.1232458
Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
pubmed: 23258412
doi: 10.1126/science.1229963
Cromer, M. K. et al. Global transcriptional response to CRISPR/Cas9-AAV6-based genome editing in CD34+ hematopoietic stem and progenitor cells. Mol. Ther. 26, 2431–2442 (2018).
pubmed: 30005866
pmcid: 6171165
doi: 10.1016/j.ymthe.2018.06.002
Skryabin, B. V. et al. Pervasive head-to-tail insertions of DNA templates mask desired CRISPR-Cas9-mediated genome editing events. Sci. Adv. 6, eaax2941 (2020).
pubmed: 32095517
pmcid: 7015686
doi: 10.1126/sciadv.aax2941
Norris, A. L. et al. Template plasmid integration in germline genome-edited cattle. Nat. Biotechnol. 38, 163–164 (2020).
pubmed: 32034391
doi: 10.1038/s41587-019-0394-6
De Ravin, S. S. et al. Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells. Blood 137, 2598–2608 (2021).
pubmed: 33623984
pmcid: 8120141
doi: 10.1182/blood.2020008503
Ward, I. M., Minn, K., van Deursen, J. & Chen, J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23, 2556–2563 (2003).
pubmed: 12640136
pmcid: 150747
doi: 10.1128/MCB.23.7.2556-2563.2003
Liu, X. et al. Overlapping functions between XLF repair protein and 53BP1 DNA damage response factor in end joining and lymphocyte development. Proc. Natl. Acad. Sci. USA 109, 3903–3908 (2012).
pubmed: 22355127
pmcid: 3309750
doi: 10.1073/pnas.1120160109
Piras, F. et al. Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. EMBO Mol. Med. 9, 1198–1211 (2017).
pubmed: 28667090
pmcid: 5582409
doi: 10.15252/emmm.201707922
Georgakilas, A. G., Martin, O. A. & Bonner, W. M. p21: a two-faced genome guardian. Trends Mol. Med. 23, 310–319 (2017).
pubmed: 28279624
doi: 10.1016/j.molmed.2017.02.001
Lattanzi, A. et al. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci. Transl. Med. 13, eabf2444 (2021).
Damian, M. & Porteus, M. H. A crisper look at genome editing: RNA-guided genome modification. Mol. Ther. 21, 720–722 (2013).
pubmed: 23542565
pmcid: 3616526
doi: 10.1038/mt.2013.46
Cromer, M. K. et al. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Nat. Med. 27, 677–687 (2021).
pubmed: 33737751
pmcid: 8265212
doi: 10.1038/s41591-021-01284-y
Gomez-Ospina, N. et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat. Commun. 10, 4045 (2019).
pubmed: 31492863
pmcid: 6731271
doi: 10.1038/s41467-019-11962-8
Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).
pubmed: 26121415
pmcid: 4729442
doi: 10.1038/nbt.3290
Wiebking, V. et al. Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica 106, 847–858 (2021).
pubmed: 32241852
doi: 10.3324/haematol.2019.233882
Srifa, W. et al. Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice. Nat. Commun. 11, 2470 (2020).
pubmed: 32424320
pmcid: 7235221
doi: 10.1038/s41467-020-16065-3
Taheri-Ghahfarokhi, A. et al. Decoding non-random mutational signatures at Cas9 targeted sites. Nucleic Acids Res. 46, 8417–8434 (2018).
pubmed: 30032200
pmcid: 6144780
doi: 10.1093/nar/gky653
Bae, S. & Kim, J.-S. Machine learning finds Cas9-edited genotypes. Nat. Biomed. Eng. 2, 892–893 (2018).
pubmed: 31015728
doi: 10.1038/s41551-018-0327-6
Nakauchi, Y. et al. The cell type-specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant preleukemia. Blood Cancer Discov. 3, 346–367 (2022).
pubmed: 35532363
pmcid: 9338760
doi: 10.1158/2643-3230.BCD-21-0143
Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136–1147.e5 (2021).
pubmed: 33626327
doi: 10.1016/j.stem.2021.02.002
Wienert, B., Wyman, S. K., Yeh, C. D., Conklin, B. R. & Corn, J. E. CRISPR off-target detection with DISCOVER-seq. Nat. Protoc. 15, 1775–1799 (2020).
pubmed: 32313254
pmcid: 7305837
doi: 10.1038/s41596-020-0309-5
Sharma, R. et al. The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. Nat. Commun. 12, 472 (2021).
Ferrari, S. et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 29, 1428–1444.e9 (2022).
pubmed: 36206730
pmcid: 9550218
doi: 10.1016/j.stem.2022.09.001
Ferrari, S. et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat. Biotechnol. 38, 1298–1308 (2020).
pubmed: 32601433
pmcid: 7610558
doi: 10.1038/s41587-020-0551-y
Lehnertz, B. et al. HLF expression defines the human hematopoietic stem cell state. Blood 138, 2642–2654 (2021).
pubmed: 34499717
doi: 10.1182/blood.2021010745
Brault, J. et al. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells. Front. Immunol. 13, 1067417 (2022).
pubmed: 36685559
doi: 10.3389/fimmu.2022.1067417
Tao, J., Bauer, D. E. & Chiarle, R. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nat. Commun. 14, 212 (2023).
pubmed: 36639728
pmcid: 9838544
doi: 10.1038/s41467-023-35886-6
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P. & Zaborowski, M. P. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 10, 4439 (2019).
pubmed: 31570731
pmcid: 6769011
doi: 10.1038/s41467-019-12449-2
Mantri, S. et al. The Binns Program for Cord Blood Research: a novel model of cord blood banking for academic biomedical research. Placenta 103, 50–52 (2021).
pubmed: 33075720
doi: 10.1016/j.placenta.2020.10.018
Wiebking, V. et al. Metabolic engineering generates a transgene-free safety switch for cell therapy. Nat. Biotechnol. 38, 1441–1450 (2020).
pubmed: 32661439
doi: 10.1038/s41587-020-0580-6
Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18–28 (2012).
pubmed: 22428977
doi: 10.1089/hgtb.2011.034
Rhiel, M. et al. T-CAST: an optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds. Front. Genome Ed. 5, 1130736 (2023).
pubmed: 36890979
pmcid: 9986454
doi: 10.3389/fgeed.2023.1130736